Sermorelin: What It Is and What It Does

What Sermorelin is

Sermorelin is GHRH(1-29), a synthetic version of the biologically active fragment of growth-hormone-releasing hormone. Rather than supplying growth hormone itself, it acts one step upstream, at the pituitary receptor that triggers the body's own release. It has a genuine clinical history — it was developed and marketed as a pharmaceutical for diagnosing and managing growth-hormone deficiency before being discontinued commercially. It is supplied here as an analytical-grade reference material for in-vitro laboratory research only.

Where it comes from

Growth-hormone-releasing hormone was characterised in the early 1980s, and researchers quickly established that its full 44-amino-acid sequence was not required — the first 29 residues carried essentially all of the receptor activity. That truncated fragment became sermorelin, which was developed pharmaceutically and used clinically, notably as a diagnostic agent for probing whether a pituitary could respond at all.

What it does — in plain terms

It binds the pituitary GHRH receptor, where it has been shown to stimulate pulsatile release of endogenous growth hormone.

How it works

Sermorelin acts at the GHRH receptor on pituitary somatotroph cells. Binding there stimulates synthesis and release of growth hormone, which is why it has been used diagnostically: if the pituitary responds, the deficiency lies upstream in the hypothalamus rather than in the gland itself.

Because it works through the body's own release machinery, the resulting pattern is pulsatile and subject to normal feedback — somatostatin still restrains release, and IGF-1 feedback still applies. This is the mechanistic distinction most often drawn in the literature between a releasing-hormone analog and administering growth hormone directly.

Its half-life in circulation is short, measured in minutes, which shapes how it has been studied and is a practical consideration in any experimental design.

What the research shows

Sermorelin has better-quality evidence behind it than most compounds in this catalog, because it was developed as a pharmaceutical and studied in that setting. The clinical literature is real, particularly around growth-hormone deficiency in children and its use as a diagnostic. Claims that extend beyond that setting — into ageing or performance — are far less supported and rest largely on mechanistic reasoning rather than trial data.

• Clinical Interventions in Aging, 2006 — Reviewed the case for GHRH-analog signalling over direct growth-hormone administration, arguing that preserving pulsatility and feedback is mechanistically preferable.
• BioDrugs, 1999 — Reviewed its established use in diagnosing and managing idiopathic growth-hormone deficiency in children — the setting where the evidence is strongest.
• Drug Testing and Analysis, 2021 — An analytical-chemistry review of how synthetic GHRH analogs are detected and measured, relevant to reference-material work.
• Annals of Translational Medicine, 2021 — Exploratory work examining GHRH-receptor signalling in a tissue context outside the pituitary.

What Sermorelin is studied for

Diagnostic endocrinology. Its best-evidenced application: testing whether a pituitary can respond to a GHRH signal, distinguishing hypothalamic from pituitary causes of deficiency.

Paediatric growth-hormone deficiency. Reviewed clinical use in children with idiopathic deficiency, where it was studied as a pharmaceutical.

Analytical detection. Because GHRH analogs are of interest in anti-doping analysis, there is a methods literature on identifying them.

Storage & handling

As a lyophilized (freeze-dried) powder, sermorelin reference material is most stable kept cold and dark — refrigerated for short-term storage, frozen for longer. Reconstitute with bacteriostatic water, refrigerate, and avoid repeated freeze-thaw; as a 29-residue peptide it is more fragile in solution than in powder form.